Peptides for menopause: a safety check on BPC-157 and other trending peptides

Name: Peptides for menopause: a safety check on BPC-157 and other trending peptides
Creator: MenoWoman

Most peptides promoted for menopause, such as BPC-157, are not approved medicines and have little or no human research behind them. Many are sold through the grey market, and the FDA has raised safety concerns about a number of them.

Researched by the MenoWoman team. Edited by Marcela Sat. Updated 7 November 2026. We may earn from links.

Get medical help quickly for fever, spreading redness, swelling or pus at an injection site, a racing heart, fainting, or a widespread rash or breathing trouble after any injection. Tell your doctor about any peptides you use, especially if you have had cancer.

What peptides are

Peptides are short chains of amino acids. Some are well-tested, approved medicines. Insulin is a peptide, and so are the GLP-1 drugs semaglutide and tirzepatide.^2,9

Bremelanotide (Vyleesi) is a peptide the FDA approved in 2019 for low sexual desire in premenopausal women.⁴ It is not approved for women after menopause.⁴

The peptides trending on social media are different. They include BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, epitalon and kisspeptin-10. They are promoted for weight loss, muscle, sleep, energy and anti-aging.^2,7 None of these is an approved menopause treatment. Many are sold to be injected.²

What the evidence shows

A 2026 review of peptides sold direct to patients found that many look promising in animals, but rigorous human safety data are scarce.⁷ For BPC-157, human evidence for injuries is limited to one small case series with no comparison group.⁸

Where human trials exist, results have been disappointing. In a trial of 114 people recovering from bowel surgery, ipamorelin worked no better than placebo.⁵ AOD-9604, a fragment of growth hormone promoted for fat loss, is not an approved weight-loss medicine. The FDA notes possible serious side effects, though it is not clear the drug caused them.¹

Kisspeptin has been studied in small lab trials. In one, 32 premenopausal women with low desire received a single hospital infusion of a different form, kisspeptin-54. Brain scans changed, but desire over time was not measured.⁶ There is no evidence that kisspeptin reverses menopause or helps brain fog. No good trials show any of these peptides help hot flashes, sleep or mood in menopause.

FDA safety concerns

The FDA keeps a list of substances nominated for compounding that may present significant safety risks. Kisspeptin-10, ipamorelin and two other growth hormone-releasing peptides are on it.¹

The FDA has also published concerns about BPC-157, TB-500, CJC-1295, MOTS-c, epitalon and others whose nominations were later withdrawn. Common concerns are unwanted immune reactions, impurities and little or no human safety data.¹ For CJC-1295, the FDA cited reports of a raised heart rate and widened blood vessels.¹

A 2026 medical review warned that unapproved peptides such as BPC-157 and TB-500 carry possible risks of abnormal blood vessel growth and cancer, as well as contamination and dosing errors.⁹ These risks are theoretical so far, because long-term human studies do not exist.^8,9

The grey market and the 2026 debate

Many peptides are sold online by unregulated makers or labeled as "research chemicals". Some products have contained contaminants or entirely different substances from the label.² Doses can vary, and users have reported infections and reactions after injections.²

In July 2025, two women aged 38 and 51 were hospitalized after peptide injections at a conference booth in Las Vegas. Both recovered.³

In late July 2026, an FDA advisory panel narrowly voted to recommend wider compounding access for six of the seven peptides it reviewed. FDA scientists said reliable data were lacking for all seven, and the FDA does not have to follow the panel.³ A panel vote is advice, not an approval, and none of these peptides is an approved medicine.

Red flags and safer routes

Warning signs include "research use only" labels on products meant for people, injections sold without a prescription, and claims to reverse aging or menopause. Promises that a peptide replaces HRT are another red flag.

For symptoms with good evidence, see hormone therapy, non-hormonal prescription treatments and strength training. If you have had cancer, talk to your cancer team before using any peptide, given the concerns about blood vessel growth.⁹ There is little or no human safety data for them, and none for pregnancy, which is still possible in perimenopause.¹

Tell your doctor and pharmacist about any peptide you use, even one bought online. This helps them spot side effects and interactions. They can also advise on any product you are considering.

What it is used for: evidence rated

Option	Evidence	What the research shows
Licensed peptide medicines, for their approved uses only	Strong evidence	GLP-1 drugs and bremelanotide passed large trials and are prescription-only. Neither is approved to treat menopause symptoms, and bremelanotide is approved only before menopause.^4,9
Weight loss (AOD-9604)	Weak evidence	Not an approved weight-loss medicine; human data are scarce and the FDA notes possible serious side effects.^1,7
Low libido (kisspeptin)	Weak evidence	One small single-infusion lab trial in premenopausal women measured brain responses, not lasting change in desire; none in menopause.⁶
Hot flashes, sleep or mood in menopause (wellness peptides)	No evidence	No published human trials in menopause; most data come from animals or the lab.⁷
Injury recovery and anti-aging (BPC-157, TB-500)	No evidence	Mainly animal and lab data, with one small uncontrolled human case series; the FDA reports little or no human safety data.^1,8

Ratings explained: how we rate. Always talk to a doctor or pharmacist before starting a medicine or supplement.